| Overview |
| bs-10467r-fitc-100ul |
| DRAK2 Polyclonal Antibody, FITC Conjugated |
| IF(ICC), IF |
| Human, Mouse, Rat |
| Specifications |
| FITC |
| Rabbit |
| KLH conjugated synthetic peptide derived from human DRAK2 |
| 281-372/372 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 9262 |
| O94768 |
| DAP kinase related apoptosis inducing protein; DAP kinase related apoptosis inducing protein kinase 2; Death associated protein kinase related 2; DRAK 2; Serine/threonine kinase 17b (apoptosis inducing); Serine/threonine kinase 17b; Serine/threonine protein kinase 17B; STK17B; ST17B_HUMAN. |
| Apoptosis is mediated by death domain containing adapter molecules and a caspase family of proteases. Certain serine/threonine protein kinases, such as ASK1 and RIP, are mediators of apoptosis. Two novel serine/threonine kinases that induce apoptosis were recently identified and designated DRAK1 and DRAK2 (for DAP kinase related apoptosis inducing protein kinases). DRAKs contain an N terminal kinase domain and a C terminal regulation domain. Overexpression of DRAK2 induces apoptosis. DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases, which mediates apoptosis through their catalytic activities. DRAK2 is located in nucleus and the messenger RNA was ubiquitously expressed in human tissues. |
| Application Dilution |
| IF(ICC) |
1:50-200 |
| IF |
|
Powered by Bioz